

ALISON TAUNTON-RIGBY, PhD, OBE

Lincoln, MA 01773

(781) 259-0488 atauntonrigby@yahoo.com



Seasoned independent director, CEO, and entrepreneur in healthcare organizations

Alison Taunton-Rigby is a business leader, entrepreneur and former Chief Executive Officer, with a record of achievement in healthcare, life sciences and financial service organizations. She has experience navigating across disciplines, business functions, cultures and scenarios with a global perspective, and known for integrity, passion and resourcefulness. Honored by Her Majesty Queen Elizabeth II as an Officer of the Order of the British Empire (OBE) for leadership in research, development and promotion of biotechnology. She has also been awarded a D.Sc. (*Honoris Causae*) by the University of Bristol, UK.

EXPERIENCED INDEPENDENT DIRECTOR

Strong credentials from over 20 year of experience as a director on corporate (public, private, ESOP, RRG), foundation, community, college and non-profit boards, and mutual fund complexes. Committed to the fiduciary responsibility of shareholder/stakeholder value. Domain knowledge includes audit, finance, strategy, compensation, and corporate governance. Understanding of industry segments includes mutual funds, investment, biotechnology, life sciences, healthcare services, and education.

EFFECTIVE LEADER

Known as an inquisitive executive, who uses new and existing resources and capabilities. Experienced with strategies for creating growth and effective innovation, particularly with companies facing transition. Leadership roles include national scale and stature.

FINANCIAL ACUMEN and EXPERTISE

Significant experience with transactions used to finance and build organizations, including venture capital, preferred stock transactions, initial public offerings, secondary offerings, PIPEs, directed stock placements, debt financing, and government contracts and grants. Experience includes merger, acquisition, divestiture, joint venture, turnaround and re-structuring situations (Chapter 11, forensic accounting). Corporate financings include transactions to raise capital (>\$1 billion).

GOVERNMENT, PUBLIC POLICY and INDUSTRY REPRESENTATION

Active at the state and national level as an industry representative through appointments to State advisory boards (Mass Life Sciences SAB), and biotechnology organizations, Massachusetts Biotechnology Council (MBC), and the Biotechnology Industry Organization (BIO). Testified before federal congressional committees and state committees on drug pricing issues, drug regulation, bioethics, stem cells and human cloning. Represented industry in negotiations with the FDA on PDUFA and drug approval issues, and animal health with the USDA.

COMMUNICATOR and PUBLIC SPEAKER involved in COMMUNITY ACTIVITIES

Invited speaker on financial services, healthcare and the corporate issues facing government officials, community leaders, the public, academics and students. Teach in a number of postgraduate courses on biotechnology, healthcare, and ethics for directors and boards. Active in promoting women's leadership worldwide through the International Women's Forum Leadership Foundation.

EXPERIENCE

RIBONOVIX, INC.

Massachusetts and Michigan

Financed and led private biotechnology company developing novel, drug resistant antibiotics.

Co-Founder, Chief Executive Officer, Director

2003 – 2010

CMT, INC.

Moultonboro, NH

Private, VC funded, medical device/health IT company, developing products for medication errors.

President, Chief Executive Officer, Director

2001 – 2003

AQUILA BIOPHARMACEUTICALS, INC. (AQLA)

Framingham, MA

Publicly traded biotechnology company engaged in the discovery, development & commercialization of products to prevent, treat or control infectious diseases, degenerative disorders and cancer.

President, Chief Executive Officer, Director

1996 – 2000

- Re-capitalized Aquila (PIPEs, direct stock placement) after Chapter 11 reorganization.
- Advanced major products through clinical development and regulatory approvals.

CAMBRIDGE BIOTECH CORPORATION (CBCX)

Worcester, MA

Publicly traded biotech company, filed for Chapter 11 protection under the bankruptcy code mid 1994.

President, Chief Executive Officer, Director

1995 – 1996

- Hired by the Board of Directors to re-structure CBC. Formulated a Plan of Reorganization, received confirmation by U.S. Bankruptcy Court in July 1996. Achieved consummation of Plan in October 1996 over many objections, appeals of the plan, stays in the Federal Bankruptcy Court, the District Court, the first Circuit Court and the U.S. Supreme Court.
- Won patent infringement lawsuits brought by Abbott Diagnostics, and Diagnostics Pasteur.
- Turned company around, built to significant profitability. Sold CBC's diagnostic businesses. Restructured pharmaceutical organization as Aquila Biopharmaceuticals.

MITOTIX, INCORPORATED

Cambridge, MA

Biotechnology company focused on the treatment of cancer and opportunistic infections.

President, Chief Executive Officer, Director

1993 – 1994

- Capitalized company through Series B financing. Recruited and built management team.

GENZYME CORPORATION (NASDAQ)

Cambridge, MA

Major, profitable, international biotechnology/healthcare company.

Senior Vice President, Biotherapeutics

1987 – 1993

- Led teams that developed Genzyme's lead products, Ceredase® and Cerezyme®, from research concept through clinical trials, FDA approval and product sales (Gaucher disease).
- Launched Ceredase® April 1991. Established global sales and marketing organization. Built worldwide revenues and profits. (Today sales are multi-billion).

ARTHUR D. LITTLE, INC., Cambridge, MA.

Sell side Healthcare analyst. Consultant to pharmaceutical companies building biotech activities.

Senior Consultant, Health Industries Management

VIVOTECH, INC., Needham, MA

Developed of an artificial pancreas for the treatment of diabetes.

Vice President and General Manager

BIOGEN, INC. (NASDAQ) Cambridge, MA

Built strategic research pipeline by in-licensing research and product development programs.

Vice President, Business Development

COLLABORATIVE RESEARCH, INC. (NASDAQ)

Advanced biotechnology research programs. Government contractor.

Vice President, Research & Development

HONOURS

2009	D.Sc. (<i>Honoris Causae</i>) University of Bristol, UK
2002	Officer of the Most Excellent Order of the British Empire (OBE), Queen Elizabeth II
2001	Presidential Medal, Worcester Polytechnic Institute
1998	Mass High Tech All-Star
1992	Face to Watch, Boston Magazine
1992	Leading Women Award, Girls Scouts of America

CURRENT BOARDS

2018 – Present	Director, TetraGenetics, Inc., (biotech company)
2016 – Present	Director, Blumont, Inc., (government contractor)
2016 – Present	Director, International Women's Forum Leadership Foundation
2002 – Present	Director, The Children's Hospital, Boston (public charity, Chair PCAC)

ACADEMIC AND INDUSTRY ACTIVITIES

2012 – Present	Advisory Board, Boston University, Health Law, Policy and Management
2011 – Present	Springboard Enterprises Life Science Council
2011 – Present	NACD NE Advisory Board (NACD NE Director 2005 – 2011)
2007 – Present	Simmons College, School of Management, Business Advisory Council
1996 – Present	Faculty, Postgraduate Course, Tufts Center for the Study of Drug Development
1994 – Present	W. Michael Hoffman Center for Business Ethics Advisory Board, Bentley University
2005 – 2011	Director, Koch Institute for Integrative Cancer Research at MIT
1996 – 2014	Director Emeritus, Biomedical Science Careers Program (career program, minorities)
1988 – 2006	Director, Massachusetts Biotechnology Council (MBC), President 1994-1996
1994 – 1999	Director, Biotechnology Industry Organization (BIO), Chair, Emerging Co. 1996-1998

GOVERNMENT APPOINTMENTS

2008 – Present	Massachusetts Life Science Center, Scientific Advisory Board
2006 – 2007	Governor Deval Patrick Transition Team
2005 – 2010	Massachusetts Biomedical Research Advisory Committee (stem cell research)
2002 – 2003	Governor Mitt Romney Transition Team
2000 – 2001	Governor's Economic Development Council (Governor Cellucci)
1997 – 2001	Education Management Accountability Board (Governors Weld and Cellucci)

REPRESENTATIVE PAST BOARDS & BUSINESS ACTIVITIES

2002 – 2017	Director, Columbia Funds, (registered investment company)
2011 – 2017	Director, ICI Mutual Insurance Company, (a risk retention group)
2004 – 2016	Director, Healthways, Inc., (NASDAQ, health and wellness services)
2001 – 2016	Director, Abt Associates Inc. (ESOP, research, consulting and technical assistance)
2000 – 2016	Director, Massachusetts Women's Forum
2006 – 2015	Board of Advisors, Civic Capital LLC
2002 – 2010	Board of Advisors, Arboretum Ventures LLC
2004 – 2010	Director, Idera Pharmaceuticals, Inc., (NASDAQ, biotechnology company)
1996 – 2007	Board of Associates, Whitehead Institute for Biomedical Research
1993 – 2003	Director, Synaptic Pharmaceuticals Corporation, Inc. (NASDAQ, biotechnology)
1997 – 2000	Director, Aquila Biopharmaceuticals Inc. (NASDAQ, biotechnology company)
1995 – 1997	Director, Cambridge Biotech Corporation (NASDAQ, life sciences company)
1994 – 1998	Director, CML Group, Inc. (NYSE, NordicTrack, Smith & Hawken, Nature Company)
1993 – 1994	Director, Mitotix, Inc. (private, biotechnology)
1992 – 1994	Director, Costar Corporation (private, laboratory equipment)
1989 – 1993	Director, Genzyme Development Partners (NASDAQ, biotechnology)

EDUCATION

Ph.D., University of Bristol, England, B.Sc., University of Bristol, England
AMP, Harvard Business School